Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMA106 Safety and PK in Healthy and Overweight/Obese Adults
NCT05054530Phase 1Completed
- Sponsor
- Gmax Biopharm
- Start
- Nov 2021
- Primary completion
- Nov 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing GMA106 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 227 days. Started Nov 2021; status: completed.
02
Drugs
ALV-100
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05054530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054530.